{{chembox
| ImageFile = Vaniprevir.svg
| ImageSize = 275
| ImageAlt =
| IUPACName = (1''R'',21''S'',24''S'')-21-''tert''-butyl-''N''-((1''R'',2''R'')-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
| OtherNames =

| Section1 = {{Chembox Identifiers
| CASNo = 923590-37-8
| ChemSpiderID = 24651717
| PubChem =
| ChEMBL = 599872
| SMILES = CC(C)(C)[C@H]1NC(=O)OCC(C)(C)CCCCc2cccc3CN(Cc23)C(=O)O[C@H]4C[C@@H](N(C4)C1=O)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)NS(=O)(=O)C6CC6
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CV3X74AO1H
 }}

| Section2 = {{Chembox Properties
| C=38|H=53|N=5|O=9|S=1
| MolarMass = 755.9 g/mol
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}

'''Vaniprevir''' (MK-7009) is a [[macrocyclic]] [[hepatitis C virus]] (HCV) [[NS3 (HCV)|NS3]]/[[NS4A|4A]] [[Protease inhibitor (pharmacology)|protease inhibitor]], developed by [[Merck & Co.]], which is currently in [[Clinical trial|clinical testing]].<ref name="pmid20163176">{{cite journal |vauthors=McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ | title = Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor | journal = J. Med. Chem. | volume = 53 | issue = 6 | pages = 2443â€“63 |date=March 2010 | pmid = 20163176 | doi = 10.1021/jm9015526 }}</ref>

In Japan, it was approved for treating [[hepatitis C]] in 2014 under the brand name '''Vanihep'''.<ref>{{cite web | url = http://www.datamonitorhealthcare.com/first-recommendation-for-hcv-drug-vaniprevir-in-japan/ | title = First recommendation for HCV drug vaniprevir, in Japan | date = September 25, 2014 | publisher = datamonitorhealthcare.com }}</ref><ref>{{cite journal | url = http://www.pmda.go.jp/files/000197902.pdf | title = New Drugs Approved | publisher = [[Pharmaceuticals and Medical Devices Agency]]}}</ref>

==References==
{{reflist}}

{{RNA antivirals}}

[[Category:Experimental drugs]]
[[Category:Cyclopropanes]]
[[Category:Macrocycles]]
[[Category:Pyrrolidines]]
[[Category:NS3/4A protease inhibitors]]
[[Category:Tert-butyl compounds]]

{{antiinfective-drug-stub}}